359 related articles for article (PubMed ID: 7840627)
21. Importance of the domain-domain interface to the catalytic action of the NO synthase reductase domain.
Welland A; Garnaud PE; Kitamura M; Miles CS; Daff S
Biochemistry; 2008 Sep; 47(37):9771-80. PubMed ID: 18717591
[TBL] [Abstract][Full Text] [Related]
22. The closed and compact domain organization of the 70-kDa human cytochrome P450 reductase in its oxidized state as revealed by NMR.
Vincent B; Morellet N; Fatemi F; Aigrain L; Truan G; Guittet E; Lescop E
J Mol Biol; 2012 Jul; 420(4-5):296-309. PubMed ID: 22543241
[TBL] [Abstract][Full Text] [Related]
23. Flavin mononucleotide-binding domain of the flavoprotein component of the sulfite reductase from Escherichia coli.
Coves J; Zeghouf M; Macherel D; Guigliarelli B; Asso M; Fontecave M
Biochemistry; 1997 May; 36(19):5921-8. PubMed ID: 9153434
[TBL] [Abstract][Full Text] [Related]
24. Role of Ser457 of NADPH-cytochrome P450 oxidoreductase in catalysis and control of FAD oxidation-reduction potential.
Shen AL; Kasper CB
Biochemistry; 1996 Jul; 35(29):9451-9. PubMed ID: 8755724
[TBL] [Abstract][Full Text] [Related]
25. On the domain structure of cytochrome P450 102 (BM-3): isolation and properties of a 45-kDa FAD/NADP domain.
Black SD
Biochem Biophys Res Commun; 1994 Aug; 203(1):162-8. PubMed ID: 8074651
[TBL] [Abstract][Full Text] [Related]
26. Potentiometric and further kinetic characterization of the flavin-binding domain of Saccharomyces cerevisiae flavocytochrome b2. Inhibition by anions binding in the active site.
Cénas N; Lê KH; Terrier M; Lederer F
Biochemistry; 2007 Apr; 46(15):4661-70. PubMed ID: 17373777
[TBL] [Abstract][Full Text] [Related]
27. The interaction of NADPH-P450 reductase with P450: an electrochemical study of the role of the flavin mononucleotide-binding domain.
Estabrook RW; Shet MS; Fisher CW; Jenkins CM; Waterman MR
Arch Biochem Biophys; 1996 Sep; 333(1):308-15. PubMed ID: 8806785
[TBL] [Abstract][Full Text] [Related]
28. Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains.
Gutierrez A; Lian LY; Wolf CR; Scrutton NS; Roberts GC
Biochemistry; 2001 Feb; 40(7):1964-75. PubMed ID: 11329263
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase.
Dong MS; Yamazaki H; Guo Z; Guengerich FP
Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680
[TBL] [Abstract][Full Text] [Related]
30. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
31. Oxidation-reduction states of FMN and FAD in NADPH-cytochrome P-450 reductase during reduction by NADPH.
Oprian DD; Coon MJ
J Biol Chem; 1982 Aug; 257(15):8935-44. PubMed ID: 6807985
[TBL] [Abstract][Full Text] [Related]
32. Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains.
Smith GC; Tew DG; Wolf CR
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8710-4. PubMed ID: 8078947
[TBL] [Abstract][Full Text] [Related]
33. Molecular dissection of human methionine synthase reductase: determination of the flavin redox potentials in full-length enzyme and isolated flavin-binding domains.
Wolthers KR; Basran J; Munro AW; Scrutton NS
Biochemistry; 2003 Apr; 42(13):3911-20. PubMed ID: 12667082
[TBL] [Abstract][Full Text] [Related]
34. Role of Asp1393 in catalysis, flavin reduction, NADP(H) binding, FAD thermodynamics, and regulation of the nNOS flavoprotein.
Konas DW; Takaya N; Sharma M; Stuehr DJ
Biochemistry; 2006 Oct; 45(41):12596-609. PubMed ID: 17029414
[TBL] [Abstract][Full Text] [Related]
35. Toxoplasma gondii ferredoxin-NADP+ reductase: Role of ionic interactions in stabilization of native conformation and structural cooperativity.
Singh K; Bhakuni V
Proteins; 2008 Jun; 71(4):1879-88. PubMed ID: 18175327
[TBL] [Abstract][Full Text] [Related]
36. Crystallization and preliminary X-ray diffraction studies of human cytochrome P450 reductase.
Zhao Q; Smith G; Modi S; Paine M; Wolf RC; Tew D; Lian LY; Primrose WU; Roberts GC; Driessen HP
J Struct Biol; 1996; 116(2):320-5. PubMed ID: 8812989
[TBL] [Abstract][Full Text] [Related]
37. Global effects of the energetics of coenzyme binding: NADPH controls the protein interaction properties of human cytochrome P450 reductase.
Grunau A; Paine MJ; Ladbury JE; Gutierrez A
Biochemistry; 2006 Feb; 45(5):1421-34. PubMed ID: 16445284
[TBL] [Abstract][Full Text] [Related]
38. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
Jin Y; Chen M; Penning TM; Miller WL
Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
[TBL] [Abstract][Full Text] [Related]
39. Functional interactions in cytochrome P450BM3. Evidence that NADP(H) binding controls redox potentials of the flavin cofactors.
Murataliev MB; Feyereisen R
Biochemistry; 2000 Oct; 39(41):12699-707. PubMed ID: 11027150
[TBL] [Abstract][Full Text] [Related]
40. Spectroscopic properties of Escherichia coli UDP-N-acetylenolpyruvylglucosamine reductase.
Axley MJ; Fairman R; Yanchunas J; Villafranca JJ; Robertson JG
Biochemistry; 1997 Jan; 36(4):812-22. PubMed ID: 9020779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
